Immunovant (IMVT) Long-Term Deferred Tax (2019 - 2020)
Immunovant (IMVT) posted Long-Term Deferred Tax of $246000.0 for Q1 2020, up 153.61% on a QoQ basis from $97000.0 in Q3 2019, and down 79.41% year-over-year from $1.2 million in Q2 2019.
Immunovant (IMVT) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
Immunovant's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $246000.0 for Q1 2020.
- Quarterly Long-Term Deferred Tax fell 79.41% year-over-year to $246000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $246000.0 (down 79.41% YoY) and the FY2020 annual result came in at $246000.0, down 79.41% from the prior year.
- Long-Term Deferred Tax was $246000.0 for Q1 2020 at Immunovant, up from $97000.0 in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $1.2 million in Q1 2019 and bottomed at $97000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Immunovant | 7.17 Bn | 7.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 246,000.00 |
| Sep 30, 2019 | 97,000.00 |
| Mar 31, 2019 | 1.20 Mn |